Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
18:03:57 EDT Wed 01 May 2024
Enter Symbol
or Name
USA
CA



Q:ALPMY - ASTELLAS PHARMA UNSP ADR EACH REPR 1 ORD - http://www.astellas.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
ALPMY - Qnot subscribed9.70+0.151.6124.51,1812369.46  9.70  9.4616.91  9.1515:59:59Mar 2815 min RT 2¢

Recent Trades - Last 10 of 236
Time ETExPriceChangeVolume
15:59:59Q9.700.15290
15:59:59Q9.700.152
15:53:37Q9.620.07402
15:51:25Q9.660.1177
15:50:05Q9.660.1153
15:48:44Q9.620.07557
15:48:38Q9.700.151
15:48:11Q9.69280.14281,731
15:46:26Q9.6520.102312
15:46:24Q9.660.111,411

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-03-28 11:00U:ALPMYNews ReleaseChina's National Medical Products Administration Accepts Astellas and Pfizer's Supplemental Biologics License Application for enfortumab vedotin with KEYTRUDA(TM) (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
2024-03-26 08:30U:ALPMYNews ReleaseAstellas Receives Permanent J-code for IZERVAY(TM) (avacincaptad pegol intravitreal solution) for Geographic Atrophy
2024-03-26 08:00U:ALPMYNews ReleaseAstellas' VYLOY(TM) (zolbetuximab) Approved in Japan for Treatment of Gastric Cancer
2024-03-22 08:00U:ALPMYNews ReleaseAstellas Receives Positive CHMP Opinion for XTANDI(TM) in Additional Recurrent Early Prostate Cancer Treatment Setting
2024-03-11 09:00U:ALPMYNews ReleaseFDA Grants Orphan Drug and Pediatric Exclusivities for CRESEMBA(TM) (isavuconazonium sulfate) for Invasive Aspergillosis and Invasive Mucormycosis in Children
2024-03-03 18:31U:ALPMYNews ReleaseAstellas Initiates Phase 3 Clinical Studies of Fezolinetant for VMS Associated with Menopause in Japan
2024-02-15 18:30U:ALPMYNews ReleasePADCEV ¢ „ ¢ (enfortumab vedotin (genetical recombination)) with KEYTRUDA ‚ ® (pembrolizumab (genetical recombination)) Granted Priority Review by Japan's Ministry of Health, Labour and Welfare for First-Line Treatment of Advanced Bladder Cancer
2024-02-15 18:30U:ALPMYNews ReleaseAstellas and Kelonia Therapeutics Enter into Research and License Agreement to Develop Novel Immuno-Oncology Therapeutics
2024-02-06 18:30U:ALPMYNews ReleaseAstellas Makes Announcement about Management Structure
2024-02-01 07:00U:ALPMYNews ReleaseAstellas to Air New VEOZAH ‚ ® (fezolinetant) TV Spot During the Super Bowl
2024-01-30 21:00U:ALPMYNews ReleaseAstellas Submits Supplemental New Drug Application in Japan for PADCEV ¢ „ ¢ (enfortumab vedotin (genetical recombination)) with KEYTRUDA ‚ ® (pembrolizumab (genetical recombination)) for First-Line Treatment of Advanced Bladder Cancer
2024-01-30 18:30U:ALPMYNews ReleaseAstellas Announces Strategic Collaboration with Mass General Brigham
2024-01-26 12:00U:ALPMYNews ReleaseEuropean Medicines Agency Validates Type II Variation Application for PADCEV ¢ „ ¢ (enfortumab vedotin) with KEYTRUDA ‚ ®(pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
2024-01-08 18:30U:ALPMYNews ReleaseAstellas Provides Update on Zolbetuximab Biologics License Application in U.S.
2023-12-28 00:53U:ALPMYNews ReleaseElpiscience and Astellas Enter into Research Collaboration and License Agreement for Novel Bispecific Macrophage Engager
2023-12-21 18:30U:ALPMYNews ReleaseAstellas Completes Acquisition of Propella Therapeutics
2023-12-17 18:35U:ALPMYNews ReleaseEMA Recommends Arpraziquantel for Treatment of Schistosomiasis in Preschool-Aged Children
2023-12-15 17:00U:ALPMYNews ReleasePADCEV ‚ ® (enfortumab vedotin-ejfv) with KEYTRUDA ‚ ® (pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer
2023-12-12 19:00U:ALPMYNews ReleaseAstellas and MBC BioLabs Announce 2023 Future Innovator Prize Awarded to TippingPoint Biosciences and Altay Therapeutics
2023-12-10 18:30U:ALPMYNews ReleaseAstellas' VEOZA ¢ „ ¢ (fezolinetant) Approved by European Commission for Treatment of Vasomotor Symptoms Associated with Menopause